逍遥散加味方治疗肝郁脾虚型抑郁症的临床效果

doi:10.20047/j.issn1673-7210.2022.28.01

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (717 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Jiawei Xiaoyao Powder in the treatment of depression with liver stagnation and spleen deficiency. Methods A total of 72 patients with mild to moderate depression of liver stagnation and spleen deficiency type admitted to the Third School of Clinical Medicine of Beijing University of Chinese Medicine from August 2020 to June 2021 were selected, according to the random number table method, they were divided into experimental group and control group, with 36 cases in each group. The experimental group was given internal application of Jiawei Xiaoyao Powder combined with Fluoxetine, and the control group was given internal application of the western medicine Fluoxetine, both of which were treated for four consecutive weeks. The antidepressant treatment effect, Hamilton depression scale (HAMD) score, traditional Chinese medicine syndrome score, and HAMD factor scores were compared between the two groups, and adverse events during the treatment were recorded. Results After treatment, the antidepressant treatment effect of the experimental group was better than that of the control group (P ＜ 0.05). Overall analysis showed that the total score of HAMD and the total score of traditional Chinese medicine syndrome had statistical significance in the comparison of time points and the difference of interaction (P ＜ 0.05). After 2 and 4 weeks of treatment, the total HAMD score and traditional Chinese medicine syndrome score of the two groups were lower than those before treatment (P ＜ 0.05). After treatment, the scores of all factors in the experimental group were better than those before treatment, while the scores of anxiety/somatization, cognitive impairment, day/night variation, delay/block, sleep disorder and hopelessness in the control group were better than those before treatment, and the scores of anxiety/somatization and sleep disorder in the experimental group were better than those in the control group (P ＜ 0.05). There was no obvious discomfort during treatment in the experimental group. One case of constipation and one case of dry mouth occurred in the control group, which were improved after patients were advised to increase dietary fiber intake and daily water intake, without drug withdrawal or special treatment. Conclusion Jiawei Xiaoyao Powder combined with Fluoxetine in the treatment of depression with liver stagnation and spleen deficiency is more effective than Fluoxetine alone, and has certain advantages in improving anxiety and depression, somatization discomfort and sleep quality, has high safety and is worthy of clinical promotion.

Key words： Depression Liver stagnation and spleen deficiency Jiawei Xiaoyao powder Fluoxetine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YUAN Jinmin1 PEI Qinghua2 QU Miao2 ZHENG Qin2

Cite this article:

YUAN Jinmin1 PEI Qinghua2 QU Miao2 ZHENG Qin2. Clinical effect of Jiawei Xiaoyao Powder in the treatment of depression with liver stagnation and spleen deficiency[J]. 中国医药导报, 2022, 19(28): 7-10,22.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.28.01 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I28/7

[1] Malhi GS，Mann JJ. Depression [J]. Lancet，2018，392（10161）：2299-2312.
[2] Huang YQ，Wang Y，Wang H，et al. Prevalence of mental disorders in China：a cross-sectional epidemiological study [J]. Lancet Psychiatry，2019，6（3）：211-224.
[3] 朱智羽，郭闫葵.中医辨证下的抑郁症病因病机及治疗概述[J].中医药临床杂志，2019，31（4）：788-791.
[4] 高贵元，黄捷，刘丹，等.抑郁症的发病机制及抗抑郁药物的研究进展[J].中国医药导报，2021，18（1）：52-55， 70.
[5] 潘恩.抗抑郁药物的不良反应分析[J].临床医药文献电子杂志，2020，7（46）：128-129.
[6] 成扬，杨雪丽，蒋健.中医药治疗郁证的研究进展[J].中国中医药现代远程教育，2021，19（6）：193-196.
[7] 任思锜，赵峰，虞鹤鸣.逍遥散治疗抑郁症的研究进展[J].中医药学报，2021，49（4）：112-116.
[8] 林映仙，杨文静，曹宁宁，等.逍遥散及其加减方的抗抑郁作用比较研究[J].中草药，2021，52（1）：137-144.
[9] American Psychiatric Association. Diagnostic and statistical manual of mental disorders [M]. Washington DC：American Psychiatric Publishing，2013：469-471.
[10] 中华中医药学会.中医内科常见病诊疗指南中医病证部分[M]北京：中国中医药出版社，2008：144-147.
[11] 唐启盛.抑郁症中医证候诊断标准及治疗方案[J].北京中医药大学学报，2011，34（12）：810-811.
[12] 张明圆.精神评定量表手册[M].长沙：湖南科学技术出版社，1998：121-126，201.
[13] 徐春燕，田金洲，时晶，等.抑郁症的中医证候特征研究[J].中华中医药学刊，2013，31（4）：810-813.
[14] 高玉广，林泯儒，刘永辉，等.刘泰教授从肝脾论治抑郁症的经验[J].中西医结合心脑血管病杂志，2019，17（1）：157-158.
[15] 翟成瑾，曲淼，许芳，等.疏肝活血方治疗肝郁血瘀型轻中度抑郁症的效果观察[J].北京中医药，2020，39（5）：471-474.
[16] 郝银丽.抗抑郁中药组分研究进展[J].西部中医药，2019， 32（11）：139-144.
[17] 江楠，于靖，杨莉，等.中药柴胡皂苷药理作用的研究进展[J].环球中医药，2018，11（5）：796-800.
[18] 张云，高博，许海军.柴胡皂苷D基于PI3K/AKT/FoxO1调节神经炎症发挥抗抑郁作用[J].实用药物与临床，2021， 24（5）：395-399.
[19] 赵慧源，田诗琪，翟春影，等.柴胡皂苷a对抑郁模型大鼠脑内神经递质及行为学的影响[J].中国医学创新，2021， 18（34）：28-32.
[20] 张辛宁，王乐琪，李莎莎，等.丹参从瘀论治抑郁症的潜在靶点及作用机制研究[J].中药新药与临床药理，2021， 32（9）：1300-1308.
[21] 张立娟，张进强，贺慧，等.丹参抗抑郁的神经免疫机制研究探讨[J].世界科学技术-中医药现代化，2017，19（8）：1289-1293.
[22] 陈琪，何祥玉，周曼佳，等.白芍的化学成分、药理作用和临床应用研究进展[J].临床医学研究与实践，2021，6（11）：187-189.
[23] 赵静，夏晓培.当归的化学成分及药理作用研究现状[J].临床合理用药杂志，2020，13（6）：172-174.
[24] 杜晨晖，崔小芳，裴香萍，等.酸枣仁皂苷类成分及其对神经系统作用研究进展[J].中草药，2019，50（5）：1258-1268.
[25] 周静，许一凡.柏子仁化学成分与药理活性研究进展[J].化学研究，2019，30（4）：429-433.
[26] 邢楠楠，屈怀东，任伟超，等.五味子主要化学成分及现代药理作用研究进展[J].中国实验方剂学杂志，2021， 27（15）：210-218.